2nd  ||| S:0 E:4 ||| NNP
international  ||| S:4 E:18 ||| JJ
workshop  ||| S:18 E:27 ||| NN
on  ||| S:27 E:30 ||| IN
Neisseria  ||| S:30 E:40 ||| NNP
vaccines  ||| S:40 E:49 ||| NNS
( ||| S:49 E:50 ||| -LRB-
Neisseria  ||| S:50 E:60 ||| NNP
vaccines  ||| S:60 E:69 ||| VBD
2009 ||| S:69 E:73 ||| CD
)  ||| S:73 E:75 ||| -RRB-
A  ||| S:75 E:77 ||| DT
5-day  ||| S:77 E:83 ||| JJ
workshop  ||| S:83 E:92 ||| NN
on  ||| S:92 E:95 ||| IN
Neisseria  ||| S:95 E:105 ||| NNP
vaccines  ||| S:105 E:114 ||| NNS
was  ||| S:114 E:118 ||| VBD
held  ||| S:118 E:123 ||| VBN
in  ||| S:123 E:126 ||| IN
Varadero ||| S:126 E:134 ||| NNP
,  ||| S:134 E:136 ||| ,
Cuba ||| S:136 E:140 ||| NNP
,  ||| S:140 E:142 ||| ,
17-22  ||| S:142 E:148 ||| NNP
May  ||| S:148 E:152 ||| NNP
2009 ||| S:152 E:156 ||| CD
,  ||| S:156 E:158 ||| ,
and  ||| S:158 E:162 ||| CC
hosted  ||| S:162 E:169 ||| VBD
by  ||| S:169 E:172 ||| IN
the  ||| S:172 E:176 ||| DT
Latin  ||| S:176 E:182 ||| NNP
American  ||| S:182 E:191 ||| NNP
Association  ||| S:191 E:203 ||| NNP
for  ||| S:203 E:207 ||| IN
Immunology  ||| S:207 E:218 ||| NNP
and  ||| S:218 E:222 ||| CC
the  ||| S:222 E:226 ||| DT
Cuban  ||| S:226 E:232 ||| JJ
Society  ||| S:232 E:240 ||| NNP
for  ||| S:240 E:244 ||| IN
Immunology ||| S:244 E:254 ||| NNP
,  ||| S:254 E:256 ||| ,
which  ||| S:256 E:262 ||| WDT
attracted  ||| S:262 E:272 ||| VBD
more  ||| S:272 E:277 ||| JJR
than  ||| S:277 E:282 ||| IN
100  ||| S:282 E:286 ||| CD
scientists  ||| S:286 E:297 ||| NNS
from  ||| S:297 E:302 ||| IN
different  ||| S:302 E:312 ||| JJ
parts  ||| S:312 E:318 ||| NNS
of  ||| S:318 E:321 ||| IN
the  ||| S:321 E:325 ||| DT
world ||| S:325 E:330 ||| NN
.  ||| S:330 E:332 ||| .
The  ||| S:332 E:336 ||| DT
meeting  ||| S:336 E:344 ||| NN
summarizes  ||| S:344 E:355 ||| VBZ
current  ||| S:355 E:363 ||| JJ
knowledge  ||| S:363 E:373 ||| NN
regarding  ||| S:373 E:383 ||| VBG
Neisseria  ||| S:383 E:393 ||| JJ
species  ||| S:393 E:401 ||| JJ
vaccine  ||| S:401 E:409 ||| NN
development ||| S:409 E:420 ||| NN
,  ||| S:420 E:422 ||| ,
including  ||| S:422 E:432 ||| VBG
plain  ||| S:432 E:438 ||| JJ
polysaccharide  ||| S:438 E:453 ||| JJ
vaccines ||| S:453 E:461 ||| NNS
,  ||| S:461 E:463 ||| ,
conjugate  ||| S:463 E:473 ||| JJ
polysaccharides  ||| S:473 E:489 ||| NN
and  ||| S:489 E:493 ||| CC
protein-based  ||| S:493 E:507 ||| JJ
vaccines ||| S:507 E:515 ||| NNS
.  ||| S:515 E:517 ||| .
Main  ||| S:517 E:522 ||| JJ
discussion  ||| S:522 E:533 ||| NN
topics  ||| S:533 E:540 ||| NNS
were  ||| S:540 E:545 ||| VBD
the  ||| S:545 E:549 ||| DT
discovery  ||| S:549 E:559 ||| NN
of  ||| S:559 E:562 ||| IN
new  ||| S:562 E:566 ||| JJ
potential  ||| S:566 E:576 ||| JJ
antigens  ||| S:576 E:585 ||| NN
with  ||| S:585 E:590 ||| IN
protective  ||| S:590 E:601 ||| JJ
capacity ||| S:601 E:609 ||| NN
,  ||| S:609 E:611 ||| ,
current  ||| S:611 E:619 ||| JJ
and  ||| S:619 E:623 ||| CC
new  ||| S:623 E:627 ||| JJ
vaccines ||| S:627 E:635 ||| NNS
,  ||| S:635 E:637 ||| ,
pathogenesis  ||| S:637 E:650 ||| NN
and  ||| S:650 E:654 ||| CC
immune  ||| S:654 E:661 ||| JJ
response ||| S:661 E:669 ||| NN
,  ||| S:669 E:671 ||| ,
clinical  ||| S:671 E:680 ||| JJ
trials  ||| S:680 E:687 ||| NNS
and  ||| S:687 E:691 ||| CC
alternative  ||| S:691 E:703 ||| JJ
correlates  ||| S:703 E:714 ||| NN
of  ||| S:714 E:717 ||| IN
protection  ||| S:717 E:728 ||| NN
and  ||| S:728 E:732 ||| CC
manufacture ||| S:732 E:743 ||| NN
,  ||| S:743 E:745 ||| ,
control  ||| S:745 E:753 ||| NN
and  ||| S:753 E:757 ||| CC
regulation ||| S:757 E:767 ||| NN
,  ||| S:767 E:769 ||| ,
gonococcus  ||| S:769 E:780 ||| JJ
vaccines ||| S:780 E:788 ||| NNS
,  ||| S:788 E:790 ||| ,
and  ||| S:790 E:794 ||| CC
adjuvant  ||| S:794 E:803 ||| NN
as  ||| S:803 E:806 ||| IN
the  ||| S:806 E:810 ||| DT
main  ||| S:810 E:815 ||| JJ
component  ||| S:815 E:825 ||| NN
of  ||| S:825 E:828 ||| IN
Neisseria  ||| S:828 E:838 ||| NNP
vaccines ||| S:838 E:846 ||| NNS
.  ||| S:846 E:848 ||| .
Seven  ||| S:848 E:854 ||| CD
keynote  ||| S:854 E:862 ||| CD
addresses ||| S:862 E:871 ||| NNS
,  ||| S:871 E:873 ||| ,
32  ||| S:873 E:876 ||| CD
oral  ||| S:876 E:881 ||| JJ
presentations ||| S:881 E:894 ||| NNS
,  ||| S:894 E:896 ||| ,
49  ||| S:896 E:899 ||| CD
posters  ||| S:899 E:907 ||| NNS
and  ||| S:907 E:911 ||| CC
an  ||| S:911 E:914 ||| DT
International  ||| S:914 E:928 ||| NNP
Vaccine  ||| S:928 E:936 ||| NNP
Course  ||| S:936 E:943 ||| NNP
were  ||| S:943 E:948 ||| VBD
presented ||| S:948 E:957 ||| VBN
.  ||| S:957 E:959 ||| .
The  ||| S:959 E:963 ||| DT
meeting  ||| S:963 E:971 ||| NN
was  ||| S:971 E:975 ||| VBD
concluded  ||| S:975 E:985 ||| VBN
with  ||| S:985 E:990 ||| IN
a  ||| S:990 E:992 ||| DT
' ||| S:992 E:993 ||| POS
Hot  ||| S:993 E:997 ||| NNP
Topics ||| S:997 E:1003 ||| NNP
'  ||| S:1003 E:1005 ||| POS
session  ||| S:1005 E:1013 ||| NN
discussing  ||| S:1013 E:1024 ||| VBG
future  ||| S:1024 E:1031 ||| JJ
challenges ||| S:1031 E:1041 ||| NNS
.  ||| S:1041 E:1043 ||| .
This  ||| S:1043 E:1048 ||| DT
article  ||| S:1048 E:1056 ||| NN
highlights  ||| S:1056 E:1067 ||| VBZ
the  ||| S:1067 E:1071 ||| DT
most  ||| S:1071 E:1076 ||| RBS
important  ||| S:1076 E:1086 ||| JJ
issues  ||| S:1086 E:1093 ||| NNS
presented ||| S:1093 E:1102 ||| VBD
.  ||| S:1102 E:1104 ||| .
